Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and development webcast the expansion of the RASP platform to include programs in central nervous system diseases associated with inflammation, and provided updated manufacturing information on reproxalap.Based on new preclinical results in models of Parkinson’s disease and amyotrophic lateral sclerosis, which included improved grip strength, balance, and biomarkers of central nervous system function, potential clinical indications for the orally administered, next-generation RASP modulator ADX-248 were expanded to include neuroinflammatory diseases that affect the central nervous system.The U.S. Food and Drug Administration (FDA) completed routine site inspections of reproxalap drug substance and drug product manufacturing facilities in 20
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript [Seeking Alpha]Seeking Alpha
- Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in LondonBusiness Wire
- Aldeyra Therapeutics (NASDAQ:ALDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.MarketBeat
- Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ETBusiness Wire
ALDX
Earnings
- 11/5/25 - Beat
ALDX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form 8-K
- 11/5/25 - Form 10-Q
- ALDX's page on the SEC website